MetaVia is trading 5.2% down at $1.64, with no clear company-specific announcement or fresh catalyst identified for September 21, 2026.
- The latest publicly reported company item remains September 9 preclinical DA-1726 data, not a new-day explanation for the decline.
- Broader markets are rising, so MetaVia is not following the prevailing risk-on direction.
- The move currently lacks an established cause.